What's Next For Cell And Gene Therapies: Addressing Challenges To Advance The State Of The Industry

The cell and gene therapy (CGT) industry is at a pivotal moment, poised for growth but facing significant challenges. While these therapies are revolutionizing patient care for a wide range of diseases, their widespread adoption hinges on overcoming hurdles in manufacturing, clinical infrastructure, reimbursement, and administration.

This excerpt from the 2024 Cell and Gene Therapy Report delves into these challenges and offers potential solutions. It highlights the need for scalable manufacturing processes, streamlined administrative procedures, and innovative payment models to ensure CGT accessibility. It also emphasizes the importance of expanding CGT care beyond major academic medical centers and into community settings through strategic partnerships and workforce training.

By addressing these challenges collaboratively, stakeholders can unlock the full potential of CGTs and transform patient care across various therapeutic areas. To learn more about the insights and proposed solutions, access the full article below.